Beyond Air Receives Nasdaq Panel Decision Granting Continued Listing – Critical Update for Investors
Beyond Air, Inc. (NASDAQ: XAIR), a commercial-stage medical device and biopharmaceutical company specializing in nitric oxide therapies, announced a significant development regarding its Nasdaq listing status. The company has received a favorable decision from the Nasdaq Hearings Panel, granting Beyond Air continued listing on The Nasdaq Stock Market. However, this decision is subject to the company regaining compliance with Nasdaq’s Bid Price Rule (Listing Rule 5550(a)(2)) by July 31, 2026.
Key Points of the Report
- Nasdaq Panel Decision: Beyond Air has been granted the opportunity to maintain its Nasdaq listing, but must resolve its bid price deficiency by July 31, 2026.
- Current Compliance: The company is in compliance with all other Nasdaq continued listing requirements.
- Reverse Stock Split Proposal: To address the bid price requirement, shareholders will vote on a proposed reverse stock split during a special meeting scheduled for June 18, 2026. If approved, the board will determine the appropriate split ratio to facilitate compliance.
- Company Focus: Beyond Air remains focused on commercial execution and advancing its next-generation portable nitric oxide platform. The company has already received FDA approval and CE Mark for its LungFit PH system, which treats hypoxic respiratory failure in neonates.
Important Information for Shareholders
- Potential Share Price Impact: The key issue at hand is the company’s ability to regain compliance with Nasdaq’s \$1 minimum bid price rule. Failure to do so by the deadline could result in delisting, which would be highly detrimental to share value and liquidity.
- Reverse Stock Split Vote: The upcoming vote on the reverse stock split is crucial. Approval and implementation of a reverse stock split is a typical method for companies to increase their share price above the minimum bid price required by Nasdaq. Shareholders should be aware that while a reverse split can help compliance, it does not directly improve the underlying business fundamentals and can sometimes be perceived negatively by the market.
- Forward-Looking Risks: The company has highlighted several risks in its forward-looking statements, including:
- The risk of not regaining compliance with the bid price rule within the required timeframe
- Uncertainty around the effectiveness of a reverse stock split in maintaining an adequate share price
- The need for continued commercial success, market adoption of LungFit PH, and expansion into new markets
- The company’s ability to secure additional financing if needed
- Future Outlook: Beyond Air’s management expresses confidence that the time afforded by the Nasdaq Panel will allow them to execute their compliance strategy while continuing to advance commercial and development initiatives.
What Could Move the Share Price?
- A successful reverse stock split and regaining compliance could stabilize or boost share price as the risk of delisting is removed.
- Conversely, failure to gain shareholder approval for the reverse split, or inability to raise the share price post-split, would put the company’s listing and share value at significant risk.
- Progress on commercial execution and updates regarding the adoption of LungFit PH, as well as development of the next-generation platform, remain key catalysts for future share price movement.
Investor Contacts
For further information, investors can contact:
Corey Davis, Ph.D.
LifeSci Advisors, LLC
Email: [email protected]
Phone: (212) 915-2577
Disclaimer: This article is not investment advice. It is a summary of publicly available information and forward-looking statements, which are subject to risks and uncertainties beyond the company’s control. Investors should review the company’s SEC filings and consult with their financial advisors before making investment decisions.
